Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIC-102 Monotherapy in Advanced Solid Tumors, NHL, and Multiple Myeloma
NCT05880043Phase 2Recruiting
- Sponsor
- GI Cell
- Start
- Apr 2023
- Primary completion
- Dec 2025
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of GIC-102 in solid tumor (advanced stage), non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) (2 arms), sponsored by GI Cell. Primary endpoints: Dose-limiting toxicity assessment at 4 weeks, Adverse event / Immune related adverse event at 1 year and 1 more. Started Apr 2023; status: recruiting.
02
Drugs
GIC-102
03
Conditions
solid tumor (advanced stage)non-Hodgkin lymphoma (NHL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05880043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05880043.